Literature DB >> 6340600

Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.

Y Sakata, A Boccazzi, G H McCracken.   

Abstract

The pharmacokinetics and bacteriological effect of ceftazidime were evaluated in rabbits experimentally infected with Streptococcus pneumoniae, Haemophilus influenzae type b, and Escherichia coli K1. The mean penetration of ceftazidime into cerebrospinal fluid after single-dose or constant-infusion administration ranged from 7.8 to 14.9%. The median cerebrospinal fluid bactericidal titers were 1:64 against S. pneumoniae and H. influenzae and 1:128 against E. coli. The bacterial colony counts in cerebrospinal fluid were reduced by 58% to 100% (-2.3 to -3.9 log10 CFU/ml) in 3 h and by 100% (-3.2 to -5.1 log10 CFU/ml) in 9 h of constant infusion, whereas in untreated infected animals, bacterial counts increased from +1.4 to +2.1 log10 CFU/ml in 9 h. These data on ceftazidime compare favorably with those on penicillin, chloramphenicol, netilmicin, and moxalactam in this experimental meningitis model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340600      PMCID: PMC186024          DOI: 10.1128/AAC.23.2.213

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

Authors:  R Wise; S Baker; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

2.  Resistance to beta-lactam antibiotics in Bacteroides species.

Authors:  C E Nord; B Olsson-Liljequist
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

3.  Clindamycin elimination in patients with liver disease.

Authors:  R H Eng; S Gorski; A Person; C Mangura; H Chmel
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

4.  Beta-lactamase-producing Bacteroides species in the oral cavity in relation to penicillin therapy.

Authors:  A Heimdahl; L von Konow; C E Nord
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

Review 5.  The tetracyclines: prospects at the beginning of the 1980s.

Authors:  I Chopra; T G Howe; A H Linton; K B Linton; M H Richmond; D C Speller
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

6.  Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.

Authors:  G H McCracken; J D Nelson; L Grimm
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

7.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  17 in total

1.  Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges.

Authors:  J S Bakken; J N Bruun; P Gaustad; T C Tasker
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Pharmacokinetics and bacteriological efficacy of ticarcillin-clavulanic acid (timentin) in experimental Escherichia coli K-1 and Haemophilus influenzae type b meningitis.

Authors:  G A Syrogiannopoulos; A Al-Sabbagh; K D Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 3.  Cephalosporins in adult meningitis.

Authors:  T R Beam
Journal:  Bull N Y Acad Med       Date:  1984-05

4.  [Comparative in vitro study of the antimicrobial activity of ceftazidime against clinical isolates].

Authors:  W Klietmann; J Focht; K Nösner
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 5.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.

Authors:  G H McCracken; Y Sakata; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental Escherichia coli and Listeria monocytogenes meningitis.

Authors:  C Odio; M L Thomas; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis.

Authors:  L Mizen; G Woodnutt; I Kernutt; E J Catherall
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 9.  The cephalosporin compounds in severe neonatal infection.

Authors:  U B Schaad
Journal:  Eur J Pediatr       Date:  1984-01       Impact factor: 3.183

10.  Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.

Authors:  Y Sakata; G H McCracken; M L Thomas; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.